Focus: City Therapeutics is a Cambridge-based RNAi biotech founded in 2018 that recently went public (ticker: CTY) to fund its pipeline of gene therapy programs. With 5,000+ employees, the company is positioned as a mid-to-large biotech with backing from Alnylam founder Maraganore.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Stable — net +3 jobs in 30d
4 added, 1 removed. Backfill posture.
Suitable for early-to-mid career scientists seeking IPO-stage upside in RNAi, but pipeline transparency issues and lack of clinical traction require careful diligence before committing.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for City Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from City Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Book value per share of City Therapeutics, Inc. – NASDAQ:CTY - TradingView
Book value per share of City Therapeutics, Inc. – NASDAQ:CTY TradingView
At its IPO close, City Therapeutics (CTY) saw ARCH buy 170,000 shares and convert preferred stock. - Stock Titan
At its IPO close, City Therapeutics (CTY) saw ARCH buy 170,000 shares and convert preferred stock. Stock Titan
At the IPO closing, ARCH bought 170,000 City Therapeutics (CTY) shares at $18 each. - Stock Titan
At the IPO closing, ARCH bought 170,000 City Therapeutics (CTY) shares at $18 each. Stock Titan
IPO conversion gives City Therapeutics (CTY) director John Maraganore 610,759 common shares. - Stock Titan
IPO conversion gives City Therapeutics (CTY) director John Maraganore 610,759 common shares. Stock Titan
Director receives 22,649 stock options with an $18 exercise price at City Therapeutics (CTY). - Stock Titan
Director receives 22,649 stock options with an $18 exercise price at City Therapeutics (CTY). Stock Titan
IPO closing fully vests 77,979 CEO options at City Therapeutics (CTY). - Stock Titan
IPO closing fully vests 77,979 CEO options at City Therapeutics (CTY). Stock Titan
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Population-Based Modeling to Predict Human PK/PD of TAK-500, an Anti-CCR2 Antibody-Drug Conjugate for First-in-Human Study in Cancer Patients.
Integration of in situ hybridization and scRNA-seq data provides a 2D topographical map of the developing retina across species.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo